Dutch VectorY Tx BV has closed one of this yerss largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.
https://european-biotechnology.com/wp-content/uploads/2024/04/VTx_pipeline.png392956Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-11-13 20:37:192024-07-09 13:40:43VectorY Therapeutics raises €129m in Series A round